Navigation Links
Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
Date:1/24/2012

PHILADELPHIA, Jan. 24, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.

"We are very excited to initiate patient enrollment in our next studies of the Symphony system in the important hospital critical care setting," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "The goal of these trials is to demonstrate Symphony's performance in the large and emerging critical care market for non-invasive continuous glucose monitoring. We believe that Symphony addresses this unmet need, potentially improving patient outcomes."

Echo's clinical studies will enroll up to thirty (30) critical care patients and will compare data obtained from its Symphony tCGM System with the YSI 2300 STAT Plus Glucose Analyzer.  The studies are expected to collect more than 1,000 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours.  The data from the studies will be blinded to study subjects and study personnel. A comparison of the data relative to the blood glucose values will be used to assess the accuracy of Symphony.

About Continuous Glucose Monitoring in Critical Care

Hyperglycemia is common in critically ill patients, even in those that do not have a history of diabetes. Intensive insulin therapy and frequent glucose monitoring in critically ill patients has been proven in clinical studies to significantly reduce patient morbidity and mortality.  Intensive insulin therapy
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
2. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
3. Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
4. Lightlake Therapeutics Inc. to Apply Companys Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
5. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
6. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
7. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
8. Echo Therapeutics Announces $3.6 Million Warrant Exercises
9. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
10. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
11. AuraSense Therapeutics Secures Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Corporation (NYSE: CVS ) today announced that ... making a presentation to investors at the Citi Investment ... Mr. Merlo is scheduled to present at 2:10 pm ... webcast of the presentation will be broadcast simultaneously through ...
... NEW YORK, May 19, 2011 Two studies ... that an improved method for performing the standard upper endoscopy ... year increases the detection of pre-cancerous cells in the esophagus ... percent over the last 25 years, making it the fastest ...
Cached Medicine Technology:Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 2Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 3Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 4
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... 01, 2014 Currently, scientists continue ... treatments for Alzheimer's disease (AD), which reflects their ... regarding the diagnosis of the disease, especially in ... appropriate diagnostic tests. In 2014, after decades ... breakthroughs in the medicine world, there are still ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... who self-paid for their antiretroviral medications experienced interruptions ... or supply logistical disruptions. These treatment interruptions led ... in patients. ,These findings by a ... Institute at Makerere University, Kampala, and UCSF are ...
... 135-2 to pass (HB 1098) a Senate-approved bill that would ... until 2011, the New York Times reports.// ,Gov. ... that mandates that all girls entering the sixth grade beginning ... the executive order will allow parents who do not want ...
... least 3 years after undergoing in vitro fertilization (IVF) ... cell// research, according to a report. ,The ... of the report, was the complete and clear explanation ... legal advisor and embryologist, which helped couples navigate the ...
... Institute is seeking to raise glaucoma awareness among Mexican-Americans,// who ... Casa Grande Valley Dispatch reports. ,Mexican-Americans over ... family history of glaucoma all face a higher risk for ... the most common form glaucoma. ,The rate ...
... music and witty tales kept Delhi audiences enthralled as spiritual ... happiness and peace. ,Far from being a moral ... Thursday on 'Circus of the mind' was a simple talk ... is a very well-coordinated activity made to look like a ...
... The amount Americans spent on arthritis medications more than ... number of people// with the disease, increases in the ... inflation-adjusted cost per prescription, according to a new study ... a six-year study of U.S. arthritis patients and the ...
Cached Medicine News:Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Treatment Cost for Arthritis on the Rise: Study 2
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Medicine Products: